MORIMATSU INTL (02155) released its annual performance, with a net profit of 584 million yuan, a year-on-year decrease of 19.95%.
Morgan Stanley (02155) announced its annual performance as of December 31, 2025. The group achieved a revenue of 6.955 billion RMB, an increase of 0.09% year-on-year; a net profit of 584 million RMB, a decrease of 19.95% year-on-year; and an earnings per share of 0.49 yuan.
Morimatsu International (02155) released its annual results for the year ending December 31, 2025. The group achieved a revenue of 6.955 billion yuan, an increase of 0.09% compared to the previous year; a net profit of 584 million yuan, a decrease of 19.95% compared to the previous year; and a basic earnings per share of 0.49 yuan.
The announcement stated that the pharmaceutical and biopharmaceutical industries, as well as the daily chemical industry, saw significant growth in revenue. However, revenue in some other industries decreased mainly due to the narrowing expansion speed of downstream industries and a slowdown in capital investment in mainland China in the short term.
Related Articles
MILAN STATION (01150): Delayed publication of 2025 full-year performance
GOLDSTREAM INV (01328) issues profit warning. It is expected that the shareholders' share of loss for the fiscal year 2025 will be approximately HK$4 million to HK$9 million.
ESSEX BIO-TECH (01061) released its annual performance, with a net profit of HKD 318 million for the year, an increase of 3.54% year-on-year.
MILAN STATION (01150): Delayed publication of 2025 full-year performance
GOLDSTREAM INV (01328) issues profit warning. It is expected that the shareholders' share of loss for the fiscal year 2025 will be approximately HK$4 million to HK$9 million.
ESSEX BIO-TECH (01061) released its annual performance, with a net profit of HKD 318 million for the year, an increase of 3.54% year-on-year.
